We don't test cells.
We read them.
Oncoptic's multi-scale optical platform interrogates cells — from population-level signal down to a single cell — with a novel sensing architecture, extracting structural, mechanical, and functional properties that no single existing test can see. Paired with an advanced signal-processing and AI-enabled SaMD, it turns that signal into a diagnostic and therapeutic tool: label-free, fast, low-cost, and built for the point of care.
A world where disease is seen at the cell — not after it's grown, spread, or progressed.
Most tests look at what's in a cell. We read what a cell is.
Structure. Mechanics. How it behaves. Captured optically — without stains, without destroying the sample. That opens applications existing tools can't reach: catching cancer earlier, and measuring how well a CAR-T therapy is actually working, cell by cell.
Built at the intersection of four fields most companies only touch one of
Biology
Knowing what cellular signal actually matters
Optics
A novel sensing architecture built to capture it
Signal Processing
Resolving raw optical signal into usable structure
AI
An AI-enabled SaMD that turns signal into insight
The team
Scientists, engineers, and entrepreneurs from MIT, Harvard, and Columbia, with a track record of successful exits
Recognition
The core technology has been recognized with the Nikola Tesla Award, the European Academy of Sciences Award, the US Star Award, and other international honors.